GlassScriptPhysician profile
Martin Guerrero
NPI 1952591935
$1,953,075.99
in general payments reported to CMS, 2019-2025
22 companies · $439K in 2025
The $439K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195K · 2020: $60K · 2021: $170K · 2022: $214K · 2023: $378K · 2024: $498K · 2025: $439K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $943K · Travel and Lodging: $196K · Consulting Fee: $117K · Food and Beverage: $45K · Honoraria: $15K · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $942,539.50 |
| Travel and Lodging | $196,064.62 |
| Consulting Fee | $116,613.00 |
| Food and Beverage | $44,615.69 |
| Honoraria | $14,850.00 |
| Education | $118.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $446,297.51 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $359,118.70 | 2023-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $310,238.56 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $233,192.68 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $220,176.56 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $130,282.63 | 2021-2025 | |
| Axsome Therapeutics, INC. | $105,848.57 | 2022-2025 | Auvelity |
| Allergan, INC. | $81,700.83 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $48,253.60 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11,840.47 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $2,337.39 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $1,068.52 | 2019-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $975.28 | 2021-2025 | Rexulti, Brintellix |
| Janssen Scientific Affairs, LLC | $483.71 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Acadia Pharmaceuticals INC | $400.49 | 2023-2024 | Nuplazid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $243.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.38 | 2023-2025 | Trintellix |
| Bioxcel Therapeutics, INC. | $115.81 | 2023-2024 | Igalmi |
| Biogen, INC. | $95.56 | 2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.67 | 2024 | |
| Novo Nordisk INC | $68.81 | 2023 | Ozempic |
| Pfizer INC. | $17.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.